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Introduction
Pancreatic cancer is the fourth leading cause of cancer
death in the United States [1,2]. Approximately
32 000 individuals in the USA and over 200 000
individuals worldwide die from the disease each year
[13]. The incidence approximates the mortality rate,
which reflects the poor prognosis of pancreatic cancer.
Although there have been many advances in pancrea-
tic cancer research, the 5-year survival rate for
affected patients remains under 5% [2].
The aggressiveness that characterizes pancreatic
cancer arises from multiple heterogeneous genetic
changes that occur before the onset of clinical symp-
toms. Studies performed over the past decade have
shed some light on the molecular and histological
events that are associated with pancreatic carcinogen-
esis. This chapter will focus on the genetics and path-
ology of pancreatic ductal adenocarcinoma. Future
progress in this area will hopefully lead to improved
diagnostic tests, early detection, and new treatments
for patients who suffer from this devastating disease.
Genetics
The accumulation of multiple nonrandom genetic
changes over time is a hallmark of pancreatic cancer.
Genetic abnormalities include alterations in chromo-
some or gene copy number, microsatellite instability,
epigenetic silencing, intragenic point mutations, and
gene overexpression secondary to increased transcrip-
tion (Table I) [4].
Chromosomal alterations
The most common techniques used to study chromo-
some losses and gains are karyotyping (G-banding),
comparative genomic hybridization (CGH), and alle-
lotyping [4]. Metaphase spread karyotyping (G-band-
ing) is a cytogenetic technique, developed in the
1960s, where chromosomes are stained and their
banding patterns are examined during metaphase.
Karyotyping can reveal large deletions, insertions,
translocations, inversions, and other rearrangements,
but suffers from a lack of submicroscopic resolu-
tion. Conventional CGH has an improved resolution
(510 mB) [5], but in the post-genomic era, even this
technology has become arcane. Array-based CGH, a
molecular cytogenetic technique developed in the
early 1990s, is an application of CGH using micro-
array technology. In microarray analysis, thousands of
molecules may be immobilized on an insoluble solid
support. This strategy enables the simultaneous
detection of a large number of analytes [6]. A second
application of microarray technology, gene expression
analysis, will be discussed in greater detail below. The
general principles of microarray analysis [7], applic-
able to both CGH and global gene expression studies,
are illustrated in Figure 1.
As demonstrated in Figure 1, fragments of tumor
DNA and non-tumor DNA are differentially labeled
with fluorescent dye and allowed to compete for
hybridization sites in either a metaphase chromosome
spread (conventional CGH) or in an array of genomic
probes (array CGH). The color and intensity of the
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fluorescence emitted by the hybridized fragments of
labeled DNA reveal areas of the genome that may be
deleted or amplified in the test sample relative to the
control sample [5,8]. In allelotyping analysis, micro-
satellite markers (short tandem repeats of DNA that
are interspersed throughout the genome) in normal
and cancer DNA from a single patient are PCR
amplified and sequenced. Since individuals are often
heterozygous at microsatellite loci, genomic deletions
can be detected by evaluating microsatellite markers
in tumor DNA for losses of heterozygosity (LOH).
Chromosome positions that have frequent LOH in
pancreatic cancer often harbor important tumor
suppressor genes [911].
Chromosome losses are more common than chro-
mosome gains in pancreatic cancer [4]. According to
allelotyping data in pancreatic cancer xenografts, DNA
loss in xenografts ranges from 1.6% to 32% of the
genome [10]. Despite this variability, certain reprodu-
cible patterns have been observed. The most common
regions of genomic loss in primary pancreatic cancers
and pancreatic cancer xenografts include chromosome
arms 9p, 17p, 18q, 3p, 8p, and 6q [10,12,13]. Some of
these loci contain known tumor suppressor genes such
as CDKN2A/P16/MTS1 (9p21), p53 (17p13), and
MADH4/SMAD4/DPC4 (18q). Further investigations
may reveal additional tumor suppressor genes in the
other LOH ‘hot spots’ [10].
Frequent gains of DNA, secondary to unbalanced
chromosome rearrangements, have been observed in
primary pancreatic cancers on chromosome arms 3q,
5p, 7p, 8q, and 20q [12,14]. Fluorescent in situ
hybridization (FISH) performed on pancreatic cancer
cell lines demonstrates amplified regions of DNA at
19q, 12p, 12q, 17q, and 20q. These amplified sites
correspond to the locations of the following onco-
genes: AKT2, KRAS2, MDM2, ERBB2 , and AIB1 ,
respectively [13,15].
Microsatellite instability
Medullary carcinoma, a subtype of pancreatic adeno-
carcinoma seen in approximately 5% of operative
cases, often contains a defective DNA mismatch
repair (MMR) mechanism [16]. Altered MMR gives
rise to microsatellite instability (MSI), characterized
by hypermutability at so-called minisatellite repeat
sequences. Unlike most ductal adenocarcinomas of
the pancreas, MSI tumors show minimal LOH and
aneuploidy [17]. They also frequently lack mutations
in KRAS2 and P53. Histologically, medullary cancers
are poorly differentiated. They grow in a syncytial
pattern, exhibit pushing borders, and demonstrate
extensive necrosis. Interestingly, these tumors appear
to have a better prognosis than the more common
ductal adenocarcinoma [16].
Epigenetic silencing
Epigenetic phenomena are heritable DNA modifica-
tions that do not involve alterations in DNA sequence
[18]. Examples include structural changes to chro-
matin, such as post-translation histone modifications
and nucleosome rearrangements, and deregulation of
cytosine methylation at promoter CpG islands. The
expression of many tumor suppressor genes and
oncogenes appears to be influenced through this
mechanism. Genes that are silenced in pancreatic
cancer by epigenetic changes include ppENK (90%),
RARB (20%), CDKN2A/P16 (18%), CACNA1G
(16%), TIMP3 (11%), CDH1 (7%), THBBS1
(7%), and hMLH1 (4%) [19,20]. Approximately
Table I. Overview of the genetic abnormalities described in this paper.
Abnormalities observed in pancreatic ductal adenocarcinoma Example
Chromosome alterations Losses: 9p, 17p, 18q, 3p, 8p, 6q Gains: 3q, 5p, 7p, 8q, 20q
Microsatellite instability Medullary carcinoma with mutations in hMLH1
Epigenetic silencing Hypermethylation of promoter CpG islands in ppENK
Mutations p16, p53, DPC4
Gene overexpression Mesothelin
Probe: Nucleic acid with known sequence 
adhered to the biochip
Target: Free nucleic acid whose presence, 
expression level, or sequence is under investigation
Cancer Control
Labled target
(genomic fragments, cDNA,
cRNA)
Targets are mixed
Cancer and control 
targets compete for
binding sites to tethered 
probes
 Black: level in cance 
 Light Grey: level in cance 
 Dark Grey: = same in cancer and control
Figure 1. Microarray technology is based on high throughput
competitive hybridization of fluorescently labeled sample DNA
and control DNA (target sequences) with an organized array of
sequences deposited on a biochip (probe sequences). Molecular
cytogenetics (e.g. CGH) and gene expression analysis (e.g. cDNA
microarray) are two widely used applications of microarray technol-
ogy. The cartoon is based on a schematic from Coe and Antler [7].
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60% of pancreatic cancers have multiple genes that
are silenced by hypermethylation of promoter cyto-
sines [20].
Mutations and specific gene alterations
Specific genes that play an important role in carcino-
genesis can be classified as tumor suppressor genes,
oncogenes, or genes involved in genomic mainte-
nance. Many tumor suppressors regulate cell prolif-
eration. Therefore, biallelic inactivation of a tumor
suppressor gene can provide a growth advantage for
tumors. Gene loss may result from allelic deletion,
intragenic mutation, chromosomal recombination,
epigenetic phenomena, or a combination thereof.
Conversely, oncogenes promote cell growth. Genetic
alterations that activate oncogenes include gain-of-
function mutations, translocations, amplifications,
and gene overexpression. Table II provides a list of
genes that affect pancreatic carcinogenesis through
intragenic mutations [21].
CDKN2A/p16/MTS1 , located on chromosome arm
9p, is the most frequently inactivated tumor suppres-
sor gene in pancreatic cancer (95%). The gene can be
inactivated through homozygous deletion (40%),
single allele loss combined with an intragenic muta-
tion in the second allele (40%), or promoter hyper-
methylation (15%) [22,23]. p16 prevents Rb-1
inhibition by CDK4-phosphorylation during G1 of
the cell cycle (Figure 2). When p16 is inactivated,
phosphorylation of Rb-1 by G1-CDKs increases,
facilitating progression through the G1/S-cell cycle
checkpoint [24].
p53, located on chromsome arm 17p, is the second
most commonly inactivated tumor suppressor gene in
pancreatic cancer (5075%) [25,26]. Usually, one
p53 allele is deleted while the other allele acquires an
intragenic mutation [25]. Following DNA damage to
normal cells, activated p53 causes the cell to arrest in
G1 or G2 of the cell cycle (Figure 2) [27]. p53 also
responds to genetic injury by activating apoptotic
pathways. Thus, p53 inactivation allows the tumor to
proliferate despite the continued accumulation of
other genetic defects.
MADH4/SMAD4/DPC4 , located on chromosome
arm 18q, is the third most frequently inactivated
tumor suppressor gene in pancreatic cancer (55%).
Approximately 30% of pancreatic cancers have homo-
zygous deletions at the SMAD4 locus, and 25% have
allelic loss with an intragenic mutation in the second
allele [28]. SMAD4 is a downstream component of
the transforming growth factor (TGF)-b and activin
signaling pathways (discussed below, Figure 3). Like
p16, loss of SMAD4 impairs the cell cycle check
mechanism during the G1/S transition. SMAD4 loss
is also believed to affect pro-apoptotic signaling [29].
Mutations have been reported in additional com-
ponents of the TGF-b and activin signaling pathways,
such as TGFbR1 (1% homozygous deletion rate),
TGFbR2 (4%), ACVR1B (2%), and ACVR2 (4%)
[30,31]. Rare mutations have also been identified in
genes outside of the TGF-b and activin pathways.
MKK4 , a component of the mitogen activated protein
kinase pathway involved in stress and cytokine-
induced signaling, has a 4% mutation rate in pan-
creatic cancer [32]. STK11/LKB1, a serine/threonine
kinase mutated in Peutz-Jeghers syndrome, is also
mutated in 4% of pancreatic cancers [33]. Recent
studies demonstrate that STK11 is important to the
maintenance of intracellular polarity and intracellular
energy metabolism [34]. BRCA2 , a genomic main-
tenance gene in the Fanconi anemia (FA) pathway, is
altered in 7% of pancreatic cancers [35], but germline
mutations can be seen in a larger proportion of
patients (17%) that cluster in pancreatic cancer
families (see below) [36]. FANCC and FANCG
are two other components in the FA pathway that
have been shown to be mutated in pancreatic cancer
(/5%) [37]. FA signaling directs homologous re-
combination after double-strand DNA breaks.
KRAS2 , located on chromosome arm 12p, is the
most commonly mutated oncogene in pancreatic
cancer (90%) [3840]. In the majority of cases,
aspartic acid is substituted for glycine at codon 12.
Additional mutational ‘hot spots’ occur in codons
13 and 61 [41]. KRAS2 functions as a GTPase
involved in intracellular signaling. Gain-of-function
mutations that impair KRAS2 GTPase activity aug-
ment downstream signaling and increase cell prolif-
eration. Pancreatic cancers with wild-type KRAS2
may have mutations in BRAF (3%) [42]. BRAF is a
serine/threonine kinase and a key downstream effector
of KRAS2 .
Table II. Genes that may be mutated in pancreatic cancer.
Gene
Chromosome
location
Percentage of pancreatic
cancers with mutations
Oncogenes
KRAS2 12p 95
BRAF 7q 3
Tumor suppressors
p16 9p 95
p53 17p 75
DPC4 18q 55
LKB1/STK11 19p 5
MKK4 17p 4
TGFBR2 3p 4
ACVR2 2q 4
ACVR1B 12q 2
TGFBR1 9q 1
Genome maintenance
BRCA2 13q 710
FANCC 9q 6
FANCG 9p 3
MLH1 3p 3
Table modified from Sohn [21].
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Gene overexpression
Altered gene expression in tumors can result from
chromosomal rearrangements, epigenetic silencing, or
mutations in genes that are upstream of a target gene.
Gene expression may be examined one gene at a time,
using techniques like Northern blot analysis, real-time
PCR, and mRNA in situ hybridization [43]. However,
recently developed techniques such as serial analysis
of gene expression (SAGE) and microarray analysis
permit simultaneous evaluation of virtually the entire
human transcriptome [43]. In SAGE analysis, mRNA
is reverse transcribed into cDNA, and then cleaved
close to the poly A tail (3’ end). These steps produce
1014 base pair fragments, or tags, that correspond to
the transcripts in the original sample RNA pool. The
tags are linked together, amplified, and sequenced.
The prevalence of each tag in the amplified product
corresponds to the expression level of a unique
transcript in the tumor RNA library [43]. Data from
the target pool can be compared to data from a
control RNA library to identify changes in gene
expression. An advantage of the SAGE technique is
that genomes do not have to be characterized before
analysis [43].
Gene expression microarrays, like genomic micro-
array analysis (i.e. CGH), involve hybridization reac-
tions between labeled targets and a library of probes
(either cDNA or oligonucleotides) that are adhered to
a biochip. However, in the case of gene expression
analysis, the labeled targets are made from cDNA
instead of genomic fragments. Therefore, the readout
provides expression data rather than cytogenetic data.
cDNA microarray analysis follows the general scheme
for microarray experiments illustrated in Figure 1.
Specifically, the RNA from tumor and non-tumor
cells is differentially labeled with fluorescent dye dur-
ing cDNA synthesis. The target cDNAs are allowed to
hybridize to the cDNA probes on the biochip in a
competitive fashion. The colors and intensities of
the hybridization products are analyzed to determine
the level of gene expression in the tumor compared to
the reference sample [7,44]. In oligonucleotide micro-
array analysis (trademarked as GeneChip by Affyme-
trix), probes that are 25 nucleotides long are
synthesized on a biochip, one nucleotide at a time.
Labeled tumor cRNA, synthesized through sequential
reverse transcription and in vitro transcription steps, is
allowed to hybridize to the chip in a non-competitive
fashion. The intensity of the signals on the GeneChip
corresponds to the level of transcript present in the
tumor RNA sample. These data can be compared to
the signal produced by the hybridization of reference
cRNA with a separate, but identical, gene chip [7].
Gene expression microarray analysis is perhaps better
suited than SAGE analysis for high-throughput in-
vestigations, but the technique requires prior char-
acterization of a group of genes in order to synthesize
a library of probes.
Global gene expression technologies have identified
hundreds of overexpressed genes in pancreatic ductal
adenocarcinoma [4553]. Our group at Johns Hop-
kins identified 422 overexpressed genes using SAGE,
cDNA microarrays, and U133 oligonucleotide arrays
[45]. Forty genes were identified by more than
one method, and six genes were detected by all three
methods. The six genes detected by each technique
are keratin 19, transglutaminase 2, stratifin retinoic
acid-induced 3, secretory leukocyte protease inhibi-
tor, and tetraspan1. Increased expression of the first
three genes listed was observed in earlier studies using
antibody detection or mass spectrometry [5456].
Familial pancreatic cancer
Focused investigations on high-risk families have
yielded new insights into the genetics of pancreatic
cancer. Registries, such as the National Familial
Pancreas Tumor Registry (NFPTR) at Johns Hop-
kins, track patients and family members at risk for
pancreatic cancer [57,58]. Inherited mutations may
account for 210% of all pancreatic cancers [5861].
Individuals with one, two, or three first degree
relatives (parent, child, or sibling) with a history of
G1M
SG2
Cdk 4 + Cyclin D
p16
p53p21
14-3-3σ, p21, Gadd45
p53
Cdk2
Activate
Inhibit
Rb-1
Figure 2. p16 and p53 regulation of the cell cycle. In normal cells, cyclin D complexes with Cdk4 during G1 of the cell cycle. This complex
inhibits Rb by phosphorylating it, allowing the cell to progress into S-phase. p16 prevents cell proliferation during stress by interfering with
the cyclin D-Cdk complex [24]. p53 responds to DNA damage by inducing p21. Activated p21 binds and inhibits G1 and G1/S-Cdks
(Cdk2), causing the cell to arrest in G1. p53 prevents entry into mitosis through the induction of 14-3-3s, p21, and Gadd45. These proteins
inactivate M-Cdks (Cdk1, Cdc2) [27]. Inactivation of p16 or p53 in pancreatic cancer promotes cell tumorigenesis.
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pancreatic cancer demonstrate risk increases for
pancreatic cancer that are approximately 6-, 18-,
and 57-fold above baseline, respectively [58]. Pan-
creatic cancer surveillance protocols in high-risk
families using endoscopic ultrasound and/or en-
doscopic retrograde cholangiopancreatography de-
monstrate that routine screening, combined with
directed pancreatectomy for suspicious lesions, can
effectively identify and treat patients with pancreatic
dysplasia prior to the onset of invasive pancreatic
cancer [62,63]. EUS-based surveillance at Johns
Hopkins identified one high-risk individual with an
asymptomatic invasive ductal adenocarcinoma. The
patient had a disease-free survival of /5 years when
Canto et al. published the study [63].
Five hereditary tumor predisposition syndromes
associated with pancreatic cancer have been identified
thus far (Table III) [64], although these known
syndromes account for only a minority (B/20%) of
familial cases. Hereditary nonpolyposis colorectal
cancer (HNPCC) is an autosomal dominant disorder
responsible for roughly 3% of colorectal cancers, and
has an estimated population prevalence of 1/740 [65].
At least six distinct DNA mismatch repair (MMR)
genes have been linked to HNPCC. Mutations in
MMR genes result in the MSI phenotype with
enhanced tumorigenesis. Individuals with HNPCC
have a 15% lifetime risk of developing pancreatic
cancer [60,66,67]. Other extra-colonic cancers in
HNPCC patients include endometrial cancer (60%),
stomach cancer (10%), ovarian cancer (12%), geni-
tourinary cancer (4%), biliary cancer (2%), nervous
system (4%), and small bowel cancer (14%) [68].
Peutz-Jeghers syndrome (PJS) is an autosomal
dominant disorder with an incidence of 1:25 000.
The disease is characterized by mucocutaneous pig-
mentations and hamartomatous intestinal polyps, due
to mutations in the serine/threonine kinase 11
(STK11/LKB1) gene. Patients with PJS have a 132-
fold increased risk of developing pancreatic cancer;
which translates into a lifetime risk of /30%
[60,67,69].
Familial atypical multiple mole-melanoma syn-
drome (FAMMM) is associated with multiple nevi,
melanomas, and extracutaneous tumors. The disease
is caused by a mutation in CDKN2A/p16 and
accounts for approximately 12% of familial pancreatic
cancers [60]. Affected individuals have a 20-fold
increased risk for developing pancreatic cancer, and
a lifetime risk that approaches 15% in some families
[70].
Familial breast and ovarian cancer syndrome is due
to mutations in the BRCA1 or BRCA2 genes.
Individuals with germline BRCA1 mutations have a
twofold risk increase of pancreatic cancer; those with
BRCA2 mutations have between a 4- and 13-fold risk
increase [7173]. Inherited BRCA2 mutations are
responsible for roughly 17% of familial pancreatic
cancer cases, which makes BRCA2 the most common
inherited defect contributing to pancreatic cancer
identified to date [35]. Ashkenazi Jews have the
highest incidence of BRCA2-deficient pancreatic
cancer. Affected individuals in this subpopulation
usually harbor the 6174delT BRCA2 mutation, which
occurs in 1% of all Ashkenazi Jews [72]. Familial
breast cancer syndrome due to a mutated BRCA2
gene carries a lifetime risk for pancreatic cancer which
approximates 7% [74].
In addition to the above described familial cancer
predisposition syndromes, familial pancreatic cancer
can be associated with hereditary pancreatitis (HP).
HP is an autosomal dominant disease caused in 70%
of the cases by a mutation in cationic trypsinogen
(protease serine 1; PRSS1) [75]. Mutations in the
serine protease inhibitor Kazal type 1 gene (SPINK1)
have also been linked to HP [76]. Mutated PRSS1 is
resistant to inactivation, leading to pancreatic auto-
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Figure 3. Signaling pathways in pancreas development. Genes that
maintain epithelial progenitor cells, and have oncogenic properties
in pancreatic cancer, appear on the left of the figure. Genes that
stimulate endocrine differentiation, and have tumor suppressor
properties in pancreatic cancer, appear on the right of the figure.
The role of three specific signaling pathways in pancreatic devel-
opment are summarized. (a) Shh signaling inhibits endocrine
differentiation. (b) Notch signaling inhibits endocrine differentia-
tion. (c) TGF-b and activin signaling promote endocrine differ-
entiation. Modified from Kim et al [85].
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digestion. Affected individuals have a 50-fold in-
creased risk of developing pancreatic cancer; their
lifetime risk approaches 40% [77].
An unidentified pancreatic cancer gene has been
mapped to chromosome arm 4q32-34 through link-
age analysis in one family, referred to as ‘family X’
[61]. Affected family members have an 80% lifetime
risk of pancreatic cancer and do not appear to be at
increased risk for extra-pancreatic tumors. The can-
cers develop earlier (median age 43 years) than
sporadic pancreatic cancer (median age 65 years)
[78] and are often associated with a prodrome of
pancreatic insufficiency [61].
In the overwhelming majority (/80%) of familial
pancreatic cancer cases, the underlying genetic pre-
disposition remains unknown. Some groups have
aggressively proposed that unaffected family members
undergo annual surveillance [61] to exclude develop-
ment of pancreatic cancer prospectively (see EUS
studies above). There is an urgent need to identify the
gene or genes responsible for the vast majority of
familial cases, so that a ‘gene test’ akin to other
familial cancers like colon or breast cancer can be
formulated for unaffected relatives of probands.
Pathology
Pancreatic cancer and development
The embryologic development of normal pancreatic
tissue can be separated into three phases. First, dorsal
and ventral buds arise from foregut endoderm. Next,
cells differentiate into exocrine and endocrine cells.
Finally, morphogenesis occurs through growth and
branching. These events result in three distinct cell
types derived from a common precursor: exocrine
acinar cells synthesize and secrete digestive proen-
zymes into pancreatic ducts; ductal cells line the
pancreatic ducts and secrete alkaline fluid; and endo-
crine cells, primarily involved in glucose homeostasis,
are clustered into structures called islets of Langer-
hans [79].
The cell type of origin in pancreatic cancer has not
been definitively characterized. Expression of acinar,
ductal, and islet cell markers have each been identified
in pancreatic ductal adenocarcinoma. In fact, markers
for gastric, duodenal, and colonic epithelium have
also been detected [80]. Experiments in transgenic
mice have led some investigators to speculate that
normal pancreata undergoes a metaplastic change
into an embryonic-like epithelium early in cancer
development. This theory is based on animal studies
which demonstrate that metaplastic mouse pancreata
develop histological and genetic changes that are
similar to changes observed in pancreatic cancer
[8183].
The link between pancreatic development and
pancreatic cancer, supported mainly by animal stu-
dies, has increased interest in certain developmental
signaling pathways. The pathways that are best
characterized include sonic hedgehog (Shh), Notch,
and TGF-b signaling (Figure 3).
In the Hedgehog (Hh) pathway, Shh binds and
inhibits the transmembrane receptor, Patched
(PTCH) (Figure 3a) [84]. This action allows
Smoothened (SMO) to initiate downstream signals
that stabilize Gli transcription factors, leading to the
induction of target Hh genes [84,85]. The pathway is
repressed during pancreatic development by TGF-b/
Table III. Hereditary tumor predisposition syndromes associated with pancreatic cancer.
Syndrome Features
Estimated lifetime risk of
pancreatic cancer* Gene
Locus
HNPCC Colorectal cancers; less commonly cancers of
the uterus, stomach, ovaries, genitourinary
system, hepatobiliary system, brain, and small
intestine
15% Common
MSH2
MLH1
Rare
PMS1
PMS2
MSH6
2p15-16
3p21
2q31
7p22
2p15-16
Peutz-Jeghers syndrome Mucocutaneous pigmentations, hamartomatous
polyps of the GI tract, and increased risk
of GI and non-GI malignancy
30% STK11/
LKB1
kinase
19p13.3
FAMMM Multiple nevi, melanomas, and increased risk
of pancreatic cancer
15% CDKN2A/p16 19p13.3
Hereditary breast and ovarian
cancer (BRCA2)
Increased risk of breast, ovarian, and pancreatic
cancer
510% BRCA2 13q12.3
Hereditary pancreatitis (HP) Recurrent pancreatitis and pancreatic cancer 40% PRSS1
SPINK1
7q35
5q32
Family X Absence of extra-pancreatic cancer and
pancreatitis; pancreatic insufficiency prior to
the onset of cancer
80% Unidentified 4q32-34
Table modified from Hansel et al. [4]. HNPCC, hereditary nonpolyposis colorectal cancer; FAMMM, familial atypical multiple mole-
melanoma syndrome; GI, gastrointestinal.
*Lifetime risk for developing pancreatic cancer for all individuals in developing countries is 1% [64].
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activin signaling [85]. This action is believed to
maintain a precursor population and curb the pro-
gression of cells towards differentiated endocrine
tissue [84,85]. Inactivated Shh during embryogenesis
can result in developmental abnormalities such as
ectopic pancreatic tissue or islet cell hyperplasia [85].
Conversely, increased Shh expression leads to the loss
of pancreatic lineage markers and the transformation
of pancreatic mesenchyme into gut mesoderm [85].
Shh pathway components are activated in pancreatic
cancer [86,87]. Increased expression of Hh factors
were observed in pancreatic cancer cell lines and
xenografts. Developmental misexpression of Shh in
murine pancreata under the control of a Pdx1
promoter resulted in genetic and histological abnorm-
alities that resemble those seen in pancreatic cancer
precursor lesions [86]. Furthermore, cyclopamine
(a SMO antagonist) and a monoclonal antibody
against Shh had a growth inhibitory effect on pan-
creatic cancer cells in vitro , suggesting a requirement
for the pathway in growth sustenance.
Notch signaling also regulates epithelial progenitors
and inhibits endocrine differentiation in the develop-
ing pancreas (Figure 3b) [84,85,88]. The Notch
pathway is triggered when Delta, Serrate, and Jagged
ligands bind Notch receptors. The intracellular com-
ponent of the activated Notch receptor interacts with
the DNA-binding protein RBP-Jk, to activate the
transcription of the hairy/enhancer-of-split genes
(Hes). Hes activation directs basic helix-loop-helix
factors (bHLH) to down-regulate differentiation-as-
sociated genes, like the endocrine activator ngn3 [85].
Oligonucleotide microarray studies detected overex-
pression of key Notch pathway components in pan-
creatic cancer [83]. Transfection of the Notch1 and
Notch2 receptors into murine pancreatic epithelium
induced acinar-to-ductal metaplasia [83]. This pro-
cess can be disrupted in vitro by g-secretase, an
enzymatic inhibitor of Notch signaling [83].
Unlike the Notch and Hh pathways, TGF-b and
activin signaling promote endocrine cell development
(Figure 3c). The TGF-b and activin ligands bind their
respective type II receptors. The type II receptors
in turn bind TGF-b and activin type I receptors, and
activate intracellular SMAD proteins [30,85]. Since
the TGF-b and activin pathways counter Hh and
Notch pathways during pancreatic development, it is
not surprising that TGF-b and activin signaling affect
tumor growth in a different manner than the Hh and
Notch pathways. As described earlier, multiple factors
in the TGF-b and activin pathways harbor inactivat-
ing mutations, suggesting that these genes are im-
portant tumor suppressors [29].
Pancreatic intraepithelial neoplasia
Dysregulated molecular signaling and the accumula-
tion of genetic changes over time result in incremental
changes in pancreatic epithelium that can be appre-
ciated microscopically [89]. A unified nomenclature
was developed in 1999 to classify intraductal pre-
cursor lesions of the pancreas, referred to as pancrea-
tic intraepithelial neoplasia (PanINs) (Figure 4)
[90,91]. PanIN-1A lesions are flat, tall columnar
cells with basally located nuclei; PAN-1B lesions
show papillary architecture; PanIN-2 lesions exhibit
nuclear abnormalities, such as a loss of polarity or
nuclear crowding; PanIN-3 lesions have marked
nuclear and cytologic abnormalities and represent
the lesions previously referred to as carcinoma in
situ of the pancreas. Invasion through the basement
membrane marks the transition from PanIN-3 to
Figure 4. Pancreatic intraepithelial neoplasia: PanIN-1A (flat), PanIN-1B (papillary), PanIN-2 (papillary with nuclear changes), and
PanIN-3 (severely atypical with mitoses, budding, and luminal necrosis). Images appear on the Johns Hopkins Pancreas Cancer Web [91].
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invasive carcinoma. PanIN lesions demonstrate a
progressive accumulation of genetic aberrations that
mirror their histologic progression. For example,
certain changes like telomere length abnormalities
and KRAS2 mutations are observed as early as in
PanIN-1 lesions [92]. p16 inactivation has often
occurred by the PanIN-2 stage [93], while certain
changes such as loss of function of SMAD4 [94],
BRCA2 [95], and p53 [96] tumor suppressor genes
occur in advanced PanIN lesions.
Mucinous cystic neoplasm
Some noninvasive pancreatic lesions can mimic
PanINs and, analogous to the latter, can be associated
with invasive pancreatic cancers in subsets of cases
[90]. Mucinous cystic neoplasms (MCN) of the
pancreas are a heterogeneous group of cystic tumors
that range from small, benign cysts to large cysts with
infiltrating adenocarcinoma (Figure 5B) [97]. The
cysts contain a cloudy fluid that stains positive for
mucin, and they are lined by tall, mucin-producing
columnar epithelium. MCNs can be large (mean
tumor diameter is 10.5 cm) and do not communicate
with the main pancreatic duct. They occur more often
in women then men, and are usually diagnosed in the
fifth decade of life. The presence of dense ovarian
stroma underneath the cyst epithelium is a defining
characteristic of MCNs [97].
MCNs may be subcategorized into four groups
based on the degree of cellular atypia (e.g. high
nuclear-cytoplasmic ratios, pleomorphism, and loss
of cell polarity) and the presence or absence of
invasion. Thus, mucinous cystadenomas lack sig-
nificant atypia and are lined by a single layer of
epithelium, borderline mucinous cystic neoplasms
exhibit papillae and have moderate nuclear atypia,
while mucinous carcinoma in situ lesions have
severe nuclear atypia. All these categories of muci-
nous cystic lesions are noninvasive and complete
surgical resection is nearly always curative [98]. In
contrast, approximately a third of MCNs are
associated with an invasive carcinoma (mucinous
cystadenocarcinoma), which demonstrate invasion of
tumor cells into the surrounding stroma, and are
associated with a 33% 5-year survival post-resection
[98].
IPMNs
Intraductal papillary-mucinous neoplasms (IPMNs)
are similar in many aspects to MCNs (Figure 5C).
For instance, IPMNs are a heterogeneous group of
tumors that include both noninvasive (60%) and
invasive (40%) neoplasms [99]. Microscopically,
they are composed of columnar, mucin-secreting cells
and can develop a papillary architecture [97]. Indeed,
MCNs and IPMNs cannot be distinguished with an
electron microscope. However, IPMNs are not asso-
ciated with ovarian stroma, and they always commu-
nicate with the pancreatic duct system. The main
pancreatic duct or major side branches are usually
dilated and mucus-filled. Therefore, mucin may be
seen oozing from the ampulla of Vater during endo-
scopic evaluation of an IPMN.
The genetic pattern in IPMNs is different from the
genetics observed in PanIN lesions and ductal ade-
nocarcinoma. Immunohistochemical studies reveal
Figure 5. (A) Normal pancreatic tissue. (B) Mucinous cystic neoplasm. (C) Intraductal papillary-mucinous neoplasms (IPMNs). (D)
Pancreatic ductal adenocarcinoma. Images appear on the Johns Hopkins Pancreas Cancer Web [91].
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that 84% of IPMNs express the SMAD4 gene,
compared with 45% of ductal adenocarcinomas of
the pancreas [100]. Furthermore, IPMNs express a
different mucin (MUC2) than PanIN lesions and
ductal adenocarcinoma (MUC1) [101].
The epithelium of IPMNs is subcategorized by a
four-tiered histologic classification scheme, like the
one described earlier for MCNs. Intraductal papil-
lary-mucinous adenomas lack significant atypia; bor-
derline IPMNs show an intermediate degree of atypia;
and IPMN carcinoma in situ demonstrate severe
atypia [102]. ‘Colloid’ (mucinous non-cystic) carci-
noma is identified in the majority of IPMNs asso-
ciated with invasive carcinoma; a tubular/ductal type
occurs in most of the remaining cases [99].
IPMNs occur equally in men and women, and they
generally arise during the seventh decade of life [99].
Demographic data suggest that the time interval
between the development of an IPMN adenoma
and progression to an IPMN with invasive cancer is
over 5 years. Five-year survival rates for resected
IPMNs without and with invasive cancer are 77% and
43%, respectively [99]. Approximately 8% of patients
with a resected benign IPMN develop a recurrence or
a second metachronous IPMN in the pancreatic
remnant [99].
Ductal adenocarcinoma
Ductal adenocarcinoma accounts for /80% of pan-
creatic cancers. Grossly, they are white-yellow and
firm masses. Sixty percent of the cases arise in the
pancreatic head, 15% in the body or tail, and 20%
involve the gland diffusely [97]. They are character-
ized microscopically by infiltrating small glands that
are lined with low-columnar, mucin-containing cells
(Figure 5D). Typically, a strong desmoplastic reaction
occurs around the cancer [97,102]. The nuclei often
demonstrate pleomorphism, hyperchromasia, loss of
polarity, and prominent nucleoli [97].
Ductal adenocarcinomas are highly aggressive can-
cers with frequent invasion of vascular, lymphatic, and
perineural tissue. Approximately 80% of surgical
specimens show disease in regional lymph nodes.
There is clinically evident disease at distant organ
sites in up to 80% of all patients who are discovered to
have pancreatic cancer. The most common sites for
distant metastases are the liver (80%), peritoneum
(60%), lung and pleura (5070%), and adrenal
glands (25%) [97]. The 5-year survival rate for
all patients with pancreatic ductal adneocarcinoma is
B/5% [2]. The 5-year survival rate is 1525% in
patients who undergo pancreaticoduoedenectomy,
and 3040% in patients who undergo pancreatico-
duoedenectomy with small tumors and node-negative
disease [103,104].
Other rare primary non-endocrine tumors of
the pancreas include adenosquamous carcinoma,
acinar cell carcinoma, giant cell carcinoma, giant
cell carcinoma with osteoclast-like giant cells, pan-
creatoblastoma, serous cystadenoma/cystadenocarci-
noma, and solid-pseudopapillary (Hamoudi)
neoplasm [97]. Table IV gives the AJCC TMN
staging system for pancreatic cancer, last revised in
2002 [105].
Conclusions
New insights into the molecular mechanisms that
underlie pancreatic carcinogenesis have emerged dur-
ing the past decade. There is a well supported model
that outlines the genetic and histological progression
of pancreatic neoplasia. Microarray analysis offers
the opportunity to study genomic copy number and
gene expression changes across the entire human
genome and transcriptome, respectively. Conse-
quently, the number of genes that are known, or
suspected, to play a role in the development of
Table IV. TNM classification of exocrine pancreatic cancer.
TNM definitions
Primary tumor (T)
TX: Primary tumor cannot be assessed
T0: No evidence of primary tumor
Tis: Carcinoma in situ
T1: Tumor limited to the pancreas, 2 cm or less in greatest
dimension
T2: Tumor limited to the pancreas, more than 2 cm in greatest
dimension
T3: Tumor extends beyond the pancreas but without involvement
of the celiac axis or the superior mesenteric artery
T4: Tumor involves the celiac axis or the superior mesenteric artery
(unresectable primary tumor)
Regional lymph nodes (N)
NX: Regional lymph nodes cannot be assessed
N0: No regional lymph node metastasis
N1: Regional lymph node metastasis
Distant metastasis (M)
MX: Distant metastasis cannot be assessed
M0: No distant metastasis
M1: Distant metastasis
AJCC stage groupings
Stage 0
Tis, N0, M0
Stage IA
T1, N0, M0
Stage IB
T2, N0, M0
Stage IIA
T3, N0, M0
Stage IIB
T1, N1, M0
T2, N1, M0
T3, N1, M0
Stage III
T4, any N, M0
Stage IV
Any T, any N, M1
From AJCC Cancer Staging Manual [105].
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pancreatic cancer has increased exponentially in
recent years.
However, there is still much to learn. Although
there are five well characterized hereditary tumor
predisposition syndromes associated with pancreatic
cancer, the genetic abnormalities responsible for
the majority of cases of familial pancreatic cancer
have not been discovered. The exact roles of putative
tumor suppressor genes and oncogenes implicated
by microarray techniques remain unclear. In addi-
tion, the contribution of complex developmental
signaling pathways (e.g. Shh, Notch, and TGF-b)
to pancreatic carcinogenesis is just beginning to be
understood.
Improved patient outcomes in pancreatic cancer
will require continued progress in cancer genetics.
The molecular analysis of serum and gastrointestinal
excreta to detect the presence of pancreatic cancer
precursor lesions is one promising area of investiga-
tion. Berthelemy et al. demonstrated the potential of
this approach 10 years ago when they discovered
KRAS2 mutations in pancreatic juice from two
patients suspected of having benign pancreatic
disease. Both patients presented with symptoms
that led to the diagnosis of pancreatic cancer /1
year after the study [106]. KRAS2 mutations have
also been identified in the stool of patients with
pancreatic carcinoma and cholangiocarcinoma
[107]. However, recent studies show that screening
pancreatic juice and stool for KRAS2 mutations
(76% and 50% specific, respectively) fails to achieve
an appropriate specificity for a relatively low pre-
valence disease like pancreatic cancer [108], man-
dating the ongoing search for new markers such as
HIP/PAP and PAP-2 [109]. While ERCP may be an
inappropriate screening test due to its invasiveness,
EUS is a promising strategy to identify subtle
parenchymal changes before they can be visualized
by CT or MR. Continued efforts to elucidate the
molecular causes of pancreatic cancer will hopefully
translate into better diagnostic tests and therapies in
the near future.
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